BioSpace News Archive

Recommendation Based on Significant Survival Benefit Demonstrated With KEYTRUDA Plus Chemotherapy Versus Chemotherapy in Phase 3 KEYNOTE-590 Trial

Study did not meet primary endpoint of fibrosis improvement by >1 stage with no worsening of NASH versus placebo

Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, announced that preclinical data of its hepcidin induction program will be presented at the upcoming European Hematology Association 2021 Virtual Congress, which will be held from June 9-17.

Two new analyses of Movantik® (naloxegol) data, from almost 900 patients, were presented at Digestive Disease Week 2021 evaluating the onset of action and symptom improvement of Movantik for a broad range of challenging opioid-induced constipation (OIC) symptoms

Virios Therapeutics, Inc. announced that clinical data was highlighted in an oral presentation at Digestive Disease Week® 2021, the premier global meeting for physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery, which was held virtually May 21 – 23, 2021.

Protagonist Therapeutics, Inc. announced that the first human subject has been dosed in a Phase 1 study of PN-232, a novel oral interleukin-23 receptor antagonist peptide.

Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced it will host a ribbon cutting ceremony and reception for national, state and local officials, employees and other members of the community, at its new corporate headquarters on May 25, 2021, from 3:00 p.m. – 6:00 p.m. Central time.

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that the first patient has been dosed in the pilot study evaluating NT-I7, a novel long-acting human IL-7, in progressive multifocal leukoencephalopathy, a rare but very aggressive, opportunistic brain infection.

Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, announced that the Company will participate in the following upcoming investor conferences

10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating virtually in the following investor conferences: William Blair 41 st Annual Growth Stock Conference Fireside Chat on Wednesday, June 2 nd at 2:20 p.m. Eastern Time/11:20 p.m. Pacific Time